Chongqing Lummy Pharmaceutical Co.,Ltd. Posted 44.7 Million Yuan Net Loss in First Three Quarters of 2022
Listen to the full version

Chongqing Lummy Pharmaceutical Co.,Ltd. (重庆莱美药业股份有限公司) (300006.SZ) reported a net loss of 44.7 million yuan in the first three quarters of 2022, reversing a net profit of 17 million yuan for the same period in the previous year.
Meanwhile, the company posted 670.9 million yuan in revenue, down 24.8% year-on-year.
At the end of the reporting period, it had 3 billion yuan in total assets and 833.3 million yuan in total liabilities, with a liability-to-asset ratio of 27.4%.
Unlock exclusive discounts with a Caixin group subscription — ideal for teams and organizations.
Subscribe to both Caixin Global and The Wall Street Journal — for the price of one.
- PODCAST
- MOST POPULAR